GlassScriptPhysician profile
Maria Rappai
NPI 1972597961
$19,797.67
in general payments reported to CMS, 2019-2025
27 companies · $5,358 in 2025
The $5,358 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $657 · 2021: $765 · 2022: $4,345 · 2023: $1,758 · 2024: $5,515 · 2025: $5,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,640 · Food and Beverage: $4,992 · Education: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,639.63 |
| Food and Beverage | $4,991.58 |
| Education | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,112.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $3,760.22 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inspire Medical Systems, INC. | $1,218.55 | 2023-2025 | Inspire |
| Abiomed | $588.72 | 2024-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $566.45 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $505.38 | 2019-2022 | |
| Genzyme Corporation | $245.79 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $242.18 | 2019-2024 | Airsupra, Fasenra, Breztri |
| Merck Sharp & Dohme LLC | $219.06 | 2019-2025 | Zerbaxa |
| Jazz Pharmaceuticals INC. | $169.61 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $138.28 | 2020-2024 | Xarelto |
| Ceribell, INC. | $132.42 | 2025 | Pocket Eeg Device |
| United Therapeutics Corporation | $116.95 | 2019 | |
| Pfizer INC. | $112.14 | 2020-2024 | |
| Siemens Medical Solutions USA, INC. | $102.80 | 2025 | Cios Spin |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $97.58 | 2020-2023 | Eliquis |
| Gilead Sciences, INC. | $85.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.27 | 2019-2025 | Ofev |
| Mallinckrodt Hospital Products INC. | $65.26 | 2025 | Acthar |
| Inari Medical, INC. | $63.67 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Genentech USA, INC. | $33.27 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $27.56 | 2025 | Dupixent |
| Covidien LP | $20.27 | 2019 | |
| Mylan Specialty L.P. | $19.68 | 2023 | Yupelri |
| Eisai INC. | $13.71 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Rappai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.